AIM-HI Women’s Venture Competition
Thursday, September 24, 2020
The AIM-HI Accelerator Fund thanks our generous sponsors and dedicated supporters for a fabulous evening on September 24, 2020, celebrating our 8 amazing semi-finalists and their companies at the Awards Ceremony for the inaugural Women’s Venture Competition. The Awards Ceremony started with revealing the People’s Choice Award for Best Pitch winner, Dr. María José Alonso of Libera Bio, and moved to announcing our top two Finalists, selected by the judging committee, Dr. Stacy Blain of Concarlo Holdings and Dr. Manijeh Goldberg of Privo Technologies.
Privo Technologies and its chief executive officer, Manijeh Goldberg, Ph.D., have been selected as the winner of the inaugural AIM-HI Women’s Venture Competition! As a result, Privo Technologies has received investment of $900,000 – $300,000 from AIM-HI and matching investment from two supporters of the Competition! These funds will serve as seed money for proof of concept and proof of value on the path to clinical trials, and eventually, to new effective therapeutics and diagnostics that will eventually save patients’ lives. Read the Press Release.
Ready to do more? DONATE NOW and help us double the impact for women scientist-entrepreneurs who are creating life-saving oncology innovations!
2020 Women’s Venture Competition Winner
Privo Technologies, based in Peabody, Massachusetts, has developed a nano-engineered platform to redesign the mechanism of action of potent cancer medicines in unconventional ways, including via a topical patch. Its technology delivers and retains high concentrations of chemotherapy drugs at tumor sites and lymph nodes in order to maximize potency and minimize toxicity. For more information, visit https://www.privotechnologies.com.
We welcome Deepa Narayanan as our Awards Ceremony Keynote Speaker for this exciting event.
Deepa is an experienced professional with expertise in commercialization of innovative healthcare technologies and a successful background in translation of oncology products to the clinic. Her experience includes non-dilutive funding strategies, portfolio management of oncology startups, identifying technology gaps, technology development, multi-center clinical trials, regulatory approval and market launch, as well as collaborating with key opinion leaders. With a special focus on connecting innovators with high-value funding and non-funding resources, Deepa has over 15 years of experience in academic, commercial and government sectors.